-
AstraZeneca's Calquence found success in lymphoma. Will CLL follow?
fiercepharma
December 06, 2018
Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma.
-
ASH: Can Johnson & Johnson sell regulators on Xarelto as clot prevention for cancer patients?
fiercepharma
December 05, 2018
Johnson & Johnson's clot-busting Xarelto may not have hit the primary goal in its latest trial, but the company still believes it can win a new approval down the line—and as the drug's laundry list of current indications shows...
-
ASH: Johnson & Johnson's fast-growing Darzalex lines up for 2nd front-line myeloma OK
fiercepharma
December 05, 2018
Johnson & Johnson’s Darzalex made multiple myeloma history this May when it became the first monoclonal antibody to score an FDA approval in newly diagnosed patients. And now, it’s looking to make it a repeat.
-
ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins
fiercepharma
December 05, 2018
Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated chronic lymphocytic leukemia (CLL). But with a new lineup of head-to-head data, the partners are looking to own it.
-
ASH: With Gamifant launch rolling, Sobi unveils more data backing the rare disease drug
fiercepharma
December 05, 2018
Armed with last month's FDA approval, Sobi is rolling out its newly minted rare disease drug Gamifant with a small, targeted sales force, and Monday it unveiled more of the data that won the agency’s favor in the first place.